bluuebunny/crossref_metadata_2025 huggingface dataset:
A24 GENERALIZABILITY OF CROHN’S DISEASE RANDOMIZED CONTROLLED TRIALS COMPARED TO CLINICAL PRACTICE
Authors: Chhibba T , Frolkis A , Ma C
Published: February 2022

Background

There are no curative medical therapies for Crohn’s disease (CD). However, multiple novel treatment options are currently being evaluated in randomized controlled trials (RCTs). Historically, CD populations enrolled in RCTs have not reflected the heterogeneity of patients observed in clinical practice due to strict inclusion/exclusion criteria and protocolized trial procedures do not reflect day-to-day care. These factors have raised concerns that results from pivotal RCTs required for drug approval are poorly generalizable.

Aims

To assess the generalizability of CD RCTs, we evaluated the proportion of CD patients initiating ustekinumab or vedolizumab in clinical care who would have been eligible for enrolment in the corresponding phase 3 registrational induction trial, and the factors impacting trial eligibility.

Methods

This is a retrospective cohort study using data from two ambulatory IBD clinics in Calgary, AB. Our study population included consecutive adult (>=18 years) patients with a confirmed diagnosis of CD, newly initiated on ustekinumab or vedolizumab between January 1, 2018 and January 1, 2020. We then applied the inclusion/exclusion criteria from the phase 3 GEMINI II/III and UNITI I/II induction trials to determine the proportion of patients who would have been trial-eligible. We then tabulated the indications for trial exclusion to determine the characteristics of patients who would not have been reflected in the trial population.

Results

A total of 50 patients were included. The median age was 42.5 years. Most patients non-stricturing non-penetrating disease (44%, 22/50) and ileocolonic disease distribution (48%, 24/50). A total of 66% (33/50) would have been eligible for inclusion in GEMINI II/III and (30/50) 60% would be eligible for inclusion in UNITI I/II. The most common reasons for trial exclusion included extensive surgery (total colectomy/subtotal colectomy) with short bowel or ileostomy (n=12), surgery within 6 months of enrolment (n=3), multiple previous resections (n=2). Four patients were excluded based on intra-abdominal abscess. A total of 13 patients (26%) were temporarily ineligible due to recent biologic switch and would have required an 8-week washout prior to trial enrolment. Only two patients were excluded based on age (>80 years).

Conclusions

Although most patients on ustekinumab or vedolizumab would have been eligible for the respective pivotal trials, patients who have complications of disease, extensive surgery, or altered anatomy are not reflected in current RCTs.

Funding Agencies

None
A27 COMPARATIVE EVALUATION OF THE ABC SCORE TO OTHER RISK STRATIFICATION SCALES IN MANAGING HIGH-RISK PATIENTS PRESENTING WITH ACUTE UPPER GASTROINTESTINAL BLEEDING
Authors: Barkun A N , Kherad O , Restellini S , Almadi M , Martel M
Published: February 2022

Background

The ABC risk score identifies patients at high-risk of mortality in acute lower and upper gastro-intestinal bleeding (UGIB).

Aims

We aimed to externally validate the ABC score, while comparing it to other prognostication scales when assessing UGIB patients at high-risk of negative outcomes prior to endoscopy.

Methods

UGIB patients from a national Canadian registry (REASON) were studied, with mortality prediction as primary outcome. Secondary endpoints included prognostication of rebleeding, intensive care unit (ICU) admission, ICU and hospitalization lengths of stay (LOS), and a previously proposed composite outcome measure. Univariable and areas under the Receiver Operating Characteristic Curve (AUROC) analyses compared discriminatory abilities of the ABC score to the AIMS65, Glasgow Blatchford (GBS) and clinical Rockall Scores.

Results

The REASON registry included 2020 patients (89.4% nonvariceal; mean age [± SD] 66.3±16.4 years; 38.4% female). Overall mortality, rebleeding, ICU admission, transfusion and composite score rates were 9.9%, 11.4%, 21.1%, 69.0%, and 67.3% respectively. ICU and hospitalization LOS were 5.4 ± 9.3 days and 9.1 ± 11.5 days, respectively. The ABC score displayed superior 30-day mortality prediction (0.78 (0.73; 0.83)) compared to GBS (0.69 (0.63; 0.75) or clinical Rockall (0.64 (0.58; 0.70) but not AIMS65 (0.73 (0.67; 0.79)). Although most scales significantly prognosticated secondary outcomes in univariable analysis except for ICU LOS, discriminatory abilities on AUROC analyses were poor.

Conclusions

ABC and AIMS65 display similar good prediction of mortality. Clinical usefulness in prognosticating secondary outcomes was modest for all scales, limiting their adoptions when informing early management of high-risk UGIB patients.

Funding Agencies

International Scientific Partnership Program ISPP at King Saud University for funding this research work through ISPP-21–156
A29 ALBUMIN UTILISATION AT A TERTIARY CARE HOSPITAL
Authors: Saad Mohammed A , Goldshtein D , Sarbar S , Wong S , Flemming J
Published: February 2022

Background

Albumin is a colloidal solution with usage guided by recommendations from Canadian Blood Services (CBS). In Ontario, rates of albumin use increased substantially from 2012 to 2018 despite the lack of development of new indications for using over this time frame. Further, we recently found that >50% of albumin usage in patients with cirrhosis were non-evidence based. Albumin usage in other patient populations is not well described.

Aims

Our aim was to describe overall usage of albumin stratified by clinical setting, clinical indication, and dosage at a tertiary care hospital.

Methods

We retrospectively identified all albumin prescriptions during two randomly selected non-consecutive months between 2018 and 2019 at Kingston Health Sciences Centre. Data was abstracted from each hospital chart for indication, prescriber specialty, location of patient, amount of albumin ordered, and concentration (5% or 25%). Albumin prescriptions were then defined as either evidence-based or non-evidence based on published literature and guidelines. Overall cost for albumin during the study period was determined based on CBS pricing ($51.47/ 25gms).

Results

A total of 699 albumin prescriptions were dispensed to 317 individuals over December 2018 and May 2019, with a total of 38,458 grams used. Overall, 36% was prescribed for evidence-based indications. The most common indication was plasmapheresis (32%), non-sepsis volume resuscitation (23%), and cardiac surgery (17%). The majority of albumin was prescribed in dialysis unit (32%), ICU (23%), and cardiac sciences unit (11%). The largest prescribers of albumin were intensivists (26%), followed by nephrologists (17%), and cardiac surgeons (15%). There were differences in utilization based on concentration of albumin. Despite limited evidence of benefit, 25% albumin and 5% albumin were used excessively for volume resuscitation and cardiac surgery respectively. When used for an evidence-based indication, the dosing was incorrect in 45% of orders. A total of $79,176 was spent on albumin during the study period. Importantly, only $28,494 was spent on evidence-based indications with appropriate dosage and concentration.

Conclusions

Overall, there is significant albumin use for indications lacking substantial evidence. This study identifies the clinical contexts in which there is opportunity to reduce non-evidence-based albumin usage and cut unnecessary expenditure. Targeted quality improvement initiatives are underway.

Funding Agencies

None
A33 ENDOSCOPIC ULTRASOUND-GUIDED GASTROJEJUNOSTOMY VERSUS SURGICAL GASTROJEJUNOSTOMY AND ENTERAL STENTING FOR THE TREATMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Benchaya J , Chen Y , Martel M , Barkun A N , Wyse J , Ferri L , Miller C S
Published: February 2022

Background

Gastric outlet obstruction (GOO), often encountered in advanced malignancy, is associated with debilitating symptoms and decreased quality of life. Traditional management of this condition has been surgical gastrojejunostomy (SGJ) or enteral stenting (ES). While SGJ is highly effective, it is invasive and associated with high rates of morbidity. ES provides a less invasive approach with a lower risk of adverse events; however, it is associated with a significant risk of stent dysfunction with increased need for reintervention. Endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) is a novel modality in the management of GOO that aims to endoscopically bypass the obstruction with a lumen-apposing metal stent, with early studies suggesting good effectiveness and safety outcomes; but the data are limited.

Aims

To perform a systematic review and meta-analysis comparing the clinical outcomes of EUS-GJ to more traditional treatments of malignant GOO.

Methods

The study protocol was prospectively registered with the PROSPERO international database. The literature was systematically searched using MEDLINE, EMBASE and Web of Knowledge databases from inception through May 2021. Studies comparing EUS-GJ to ES or SGJ in patients with malignant GOO were included. Meta-analysis was performed with results reported as odds ratios (ORs) with 95% confidence intervals (CIs) using random effects models. The two primary outcomes of interest were clinical success without GOO recurrence and adverse events. Secondary outcome was technical success.

Results

Ten studies with a total of 1016 patients were included. EUS-GJ was associated with higher clinical success without GOO recurrence compared to SGJ or ES [OR: 2.19, 95% CI: 1.18–4.09, heterogeneity: P = 0.10; I2 = 59%]. Subgroup analysis showed higher clinical success without GOO recurrence compared to ES [OR: 5.31, 95% CI: 3.07–9.17], but no significant difference compared to SGJ [OR: 1.69, 95% CI: 0.76–3.72]. EUS-GJ was associated with fewer adverse events compared to SGJ and ES [OR: 0.28, 95% CI: 0.14–0.55] and compared to SGJ alone [OR: 0.20, 95% CI: 0.10–0.37], but no difference was noted when compared to ES alone [OR: 0.53, 95% CI: 0.15–1.87]. EUS-GJ was associated with decreased technical success compared to SGJ and ES [OR: 0.26, 95% CI: 0.09 – 0.75] and SGJ alone [OR: 0.14, 95% CI: 0.04–0.48]; however, there was no difference when compared to ES alone [OR: 0.43, 95% CI: 0.05–3.44].

Conclusions

EUS-GJ provides a robust bypass with lower risk of recurrent obstruction compared to ES and fewer adverse events compared to SGJ. High quality prospective studies are needed to further characterize the role of EUS-GJ in the management of malignant GOO.

Funding Agencies

None
A52 GUT-INNERVATING TRPV1+ NEURONS DRIVE CHRONIC VISCERAL PAIN VIA MICROGLIAL P2Y12 RECEPTOR
Authors: Defaye M , Abdullah N , Iftinca M , Hassan A , Agosti F , Zhang Z , Cumenal M , Zamponi G W , Altier C
Published: February 2022

Background

Long-lasting changes in neural pain circuits precipitate the transition from acute to chronic pain in patients living with inflammatory bowel diseases (IBDs). While significant improvement in IBD therapy has been made to reduce inflammation, a large subset of patients continues to suffer throughout quiescent phases of the disease. Peripheral and central mechanisms contribute to the transition from acute to chronic pain during active disease and clinical remission. Lower mechanical threshold and hyperexcitability of visceral afferents induce gliosis in central pain circuits, leading to persistent visceral hypersensitivity (VHS). In the spinal cord, microglia, the immune sentinels of the central nervous system, undergo activation in multiple models of VHS. Using the Dextran Sodium Sulfate (DSS) model of colitis, we found that microglial G-CSF was able to sensitize colonic nociceptors that express the pain receptor TRPV1. While TRPV1+ nociceptors have been implicated in peripheral sensitization, their contribution to central sensitization via microglia remains unknown.

Aims

Here we investigated the mechanisms of microglia activation to identify centrally acting analgesics for chronic IBD pain.

Methods

Using Designer Receptors Exclusively Activated by Designer Drugs (DREADD) expressed in TRPV1-expressing visceral neurons that sense colonic inflammation, we tested whether neuronal activity was indispensable to control microglia activation and VHS. We then investigated the neuron-microglia signaling system involved in visceral pain chronification.

Results

We found that chemogenetic inhibition of TRPV1+ visceral afferents prevents microglial activation in the spinal cord and subsequent VHS in colitis mice. In contrast, chemogenetic activation, in the absence of colitis, enhanced microglial activation associated with VHS. We identified a purinergic signaling mechanism mediated by neuronal ATP and microglial P2RY12 receptor, triggering VHS in colitis. Inhibition of P2RY12 prevented microglial reactivity and chronic VHS post-colitis.

Conclusions

Overall, these data provide novel insights into the central mechanisms of chronic visceral pain and suggest that targeting microglial P2RY12 signaling could be harnessed to relieve pain in IBD patients who are in remission.

Funding Agencies

CCC
A60 THE NEURAL SIGNAL, CALCITONIN GENE-RELATED PEPTIDE (CGRG) ENHANCES A REGULATORY PHENOTYPE IN THE HUMAN IL-4 TREATED HUMAN MACROPHAGE
Authors: Callejas Pina B E , Wang A , Hamed S , Mckay D M
Published: February 2022

Background

Recent studies in pre-clinical models of disease have revealed the ability of murine and human IL-4-treated macrophages (M(IL4)) to promote wound recovery and reduce the severity of colitis. An unbiased RNA-sequence analysis of human blood-derived macrophages revealed increased expression of the RAMP1 chain of the CGRP receptor in IL-4 treated cells, raising the intriguing possibility of neural control of regulatory macrophages in the context of neuroimmune interaction in colitis. Thus, we sought to address if this mRNA signal translated into increased RAMP1 protein, if/how CGPR affected M(IL4) function, and if this applied to macrophages from patients with IBD as well as those from healthy donors.

Aims

To determine if CRGP-RAMP1 signalling in human IL-4 treated macrophages enhances a regulatory phenotype.

Methods

Peripheral blood mononuclear cells from healthy volunteers and individuals with IBD were cultured on plastic (2h, 37°C) and non-adherent cells removed. The adherent cells were cultured with recombinant hM-CSF (10 ng/ml) for 7 days. The resultant macrophages (2.5×105) were differentiated with IL-4 (48h 20 ng/mL) and assessed by qPCR and immunocytochemistry. In other cells, CGRP (10 nM) was added 24h after IL-4 and (1) cAMP (2) cytokines and (3) phagocytosis of inert FITC-beads measured, and (4) the capacity of supernatant from the cells to promote healing in wounded Caco2 epithelial monolayers tested.

Results

Compared to non-treated macrophages (M(0)), M(IL4)s from healthy individuals had increased mRNA for both chains of the CGRP-receptor (i.e. RAMP1 and CLR), and increased surface expression of the receptor as shown by immunostaining and CGRP-evoked cAMP. The IL-4 evoked RAMP1 mRNA was only detected in macrophages from 50% of the patients with active IBD. M(IL4)s treated with CGRP showed enhanced expression of the mannose receptor (CD206, allows detection of bacteria), increase phagocytosis of inert beads/macrophages. Moreover, CGRP increases VEGF and CCL18 expression in M(IL4), and soluble mediators from these cells promoted in vitro epithelial wound repair.

Conclusions

Reduced expression of CGRP and its receptor has been shown in IBD. The findings herein, demonstrating how CGRP-RAMP1 signalling can reinforce and enhance a regulatory, reparatory phenotype in human macrophages reveals another aspect of IBD pathophysiology. We speculate that loss of this neuroimmune axis (i.e. CGRP/Nerve-M(IL4) interaction) has the potential to significantly impair mucosal healing in IBD.

Funding Agencies

CCCAlberta Innovates in Health Innovation
A66 THE IMPACT OF A MULTIDISCIPLINARY ADOLESCENT AND YOUNG ADULT (AYA) INFLAMMATORY BOWEL DISEASE (IBD) ON CLINIC NO SHOW RATES
Authors: Sharma R , Halder S L , Zachos M , Radoja C , Grant C , Chauhan U , Brackenridge E , Issenman R , Sherlock M , Dowhaniuk J K , Pai N , Brill H , Ratcliffe E , Narula N , Marshall J , Prowse K
Published: February 2022

Background

Transitioning from pediatric to adult health care is associated with significant psychosocial and clinical morbidity. Adolescents not only transition their medical care, but also experience vast changes in the physical, social, and psychological spheres of their lives. The medical team must help navigate these changes to provide optimal care.

IBD in adolescence is associated with increased hospitalizations and surgery. This is due to several factors, including medication non-adherence and a failure to attend medical appointments. There has been a greater focus on improving care for this unique population.

McMaster Children’s Hospital has integrated the AYA IBD clinic for patients between the ages of 16 and 22. The goal is to transition patients using a developmentally appropriate framework to facilitate self-efficacy and help identify comorbid mental health conditions while building resilience.

Aims

To explore the impact of the implementation of a dedicated transition clinic on attendance at medical visits for AYA patients with IBD.

Methods

The total numbers of patients booked in the AYA IBD Clinic was compared to an age matched subset of the patients in the adult McMaster Complex IBD (CIBD) Clinic. These visits were assessed based on whether the visit was: attended, cancelled, or no showed. Visits were then stratified between in-person and virtual visits. Unpaired t tests was performed to compare the AYA IBD clinic and the CIBD clinic. Findings were deemed significant based on p-values <0.05.

Results

The percentages of patients that attended visits (in-person or virtually) was similar between both clinics at 86% versus 79% Year 1 (Y1) and 76% versus 81% Year 2 (Y2). The number of patients seen in the AYA clinic increased from Y1 (n=92) to Y2 (n=131). The CIBD clinic saw fewer patients between Y1 (n=202) and Y2 (n=79). There were a higher number of patients who cancelled or no showed in Y2 versus Y1 for the AYA virtual visits (13 versus 8) compared to the CIBD clinic (Y2,1 versus Y1,1).

Conclusions

Our results highlight the challenges of transitioning adolescent patients with IBD. Our retrospective study was not powered to show significance. Given the increase in cancellation and no-show rates in Y2, the AYA clinic has incorporated a patient navigator to issue reminder phone calls and facilitate communication with patients between clinics. Future studies will re-assess how the presence of a patient navigator impacts attendance and cancellation rates. Future studies will also assess how the AYA clinic impacts transition readiness and self-efficacy, which is being measured through validated questionnaires in our clinic.

Funding Agencies

Grants-In-Aid
A68 THERAPEUTIC EFFECTS OF MEDICINAL CANNABINOIDS ON THE GASTROINTESTINAL SYSTEM IN PEDIATRIC PATIENTS: A SYSTEMATIC REVIEW
Authors: Sunil M , Karimi P , Leong R , Zuniga-Villanueva G , Ratcliffe E
Published: February 2022

Background

Changes in cannabis legalization in recent years have led to an increasing interest in medicinal cannabinoids for a variety of therapeutic uses, including those which target the gastrointestinal tract. These effects are mediated by interactions with the endocannabinoid system. As this system is present in early life, it is important to ensure pediatric representation in clinical studies regarding cannabinoid use.

Aims

We conducted a systematic review to assess the efficacy of medicinal cannabinoids in treating gastrointestinal symptoms in pediatric patients.

Methods

A literature search of Medline, Embase, CINAHL, Web of Science and the Cochrane Library was conducted from inception. Study design, patient characteristics, type, dose and duration of medicinal cannabinoid therapy, and gastrointestinal outcomes were extracted.

Results

From 7,303 records identified, five studies met all inclusion criteria. The focus of the included studies ranged from chemotherapy-induced nausea, inflammatory bowel disease and gastrointestinal symptoms associated with severe complex motor disorders. Results varied based on the symptom being treated, the type of cannabinoid, and the patient population, however, the most consistently improved symptom was chemotherapy-induced nausea.

Conclusions

Medicinal cannabinoids may have a potential role in treating specific gastrointestinal symptoms in specific patient populations. The limited number and heterogenicity of included studies highlight the requirement for future research to distinguish the effects amongst different cannabinoid types, patient populations and examine drug-interactions. In addition, the molecular interplay between disease processes, the endocannabinoid system and medicinal cannabinoids require investigation to further understand the mechanisms behind this intervention.

Funding Agencies

Natural Sciences and Engineering Research Council of Canada; Farncombe Family Digestive Health Research Institute
A70 SEVERE ENTERITIS AND IGA VASCULITIS IN A PEDIATRIC PATIENT WITH ULCERATIVE COLITIS ON VEDOLIZUMAB
Authors: Desai T , Jurencak R , Nair A , Carman N
Published: February 2022

Background

Pediatric Ulcerative Colitis (UC) is often unsatisfactorily controlled using ‘conventional’ therapies, thus there has been increasing use of biologic therapies and small molecules to try and improve rates of clinical remission and mucosal healing. Consequently, pediatric gastroenterologists and generalists should be aware of the complications and side effects of these newer molecules. Vedolizumab (VDZ) is a fully humanised anti-integrin therapy that is thought to limit systemic side effects given its gut-specific mechanism.

Aims

Here we report the unique case of a 14-year-old male with UC on vedolizumab presenting with severe abdominal pain, GI bleeding, markedly elevated inflammatory markers and subsequent purpura.

Methods

N/A

Results

A diagnosis of IgA vasculitis (IgAV) was made after extensive imaging, endoscopy and subspecialty consultation. Clinical course was complicated but ultimately responded to high dose steroid treatment without cessation of VDZ.

Conclusions

This case illustrates a potentially independent pathway behind IgAV in a patient on a gut-selective therapy with UC. This is the first pediatric case of vasculitis in a patient with UC on VDZ.

Funding Agencies

None
A71 POLYP TO ADENOMA CONVERSION FACTOR AS A SURROGATE FOR ADENOMA DETECTION RATE-– FINDINGS FROM THE SOUTHWEST ONTARIO COLONOSCOPY COHORT
Authors: Alobaid S , Mcdonald C , Guizzetti L , Yan B , Jairath V , Sey M
Published: February 2022

Background

The adenoma detection rate (ADR) is one of the main quality indicators of a colonoscopy but requires combining endoscopic and histologic data. However, the polyp detection rate (PDR) requires only endoscopic assessment and has been proposed as a proxy measure for the ADR.

Aims

To calculate a conversion factor for PDR to ADR, for use as a future surrogate of ADR when only PDR is available.

Methods

The Southwest Ontario Colonoscopy cohort consists of all outpatient colonoscopies performed across 20 hospitals in Southwestern Ontario between April 2017 and February 2018. Data was collected prospectively through a mandatory quality assurance form that was completed after each procedure and pathology reports were manually reviewed. Endoscopies with associated histologic findings were included.

The PDR and true ADR were calculated for each physician. A weighted polyp to adenoma detection rate quotient (APDRQ) was calculated, weighting each physician’s APDRQ by the number of procedures performed. The APDRQ was determined for all outpatient procedures and specifically for screening/surveillance indications.

Results

During the study period, 57 endoscopists performed 31,721 colonoscopies. The overall PDR was 41.1% and the ADR was 26.5%. The weighted ADPDRQ was 0.638 (95% CI: 0.600, 0.675). When limited to screening/surveillance colonoscopies, the weighted ADPDR was 0.616 (95% CI: 0.564, 0.669). To better understand the influence of endoscopists with low ADR: PDR, we excluded those with ratio below (<2 standard errors) the average, which resulted in greater ADR: PDR for all colonoscopies 0.695 (95% CI: 0.679, 0.711) and for screening/surveillance colonoscopies and 0.692 (95% CI: 0.677, 0.707).

Conclusions

In this large, population-based, cohort study, we calculated the ADR; PDR ratio. We propose this may be used in future studies to infer ADR when only PDR is available.

Scatter plot of correlation between ADR and PDR, by physician. The dashed line indicates the line for which ADR=PDR, the maximum value the ADR can take for a given PDR. The marker size is proportional to the number of colonoscopies performed.

Funding Agencies

None
A76 MEDICATION ADHERENCE AND BELIEFS ABOUT MEDICATION AND THE CORRELATION WITH KNOWLEDGE ABOUT INFLAMMATORY BOWEL DISEASE (IBD) IN PREGNANCY
Authors: Govardhanam V , Tandon P , Jogendran R , Huang V
Published: February 2022

Background

Inflammatory bowel disease (IBD) is a group of chronic inflammatory conditions including ulcerative colitis (UC), Crohn’s disease (CD) or IBD-unclassified that affect women of childbearing age. women with IBD have poor knowledge of disease management during pregnancy, as demonstrated by studies using the validated Crohn’s and Colitis Pregnancy Knowledge (CCPKnow) tool. These patients who lack knowledge about IBD and reproduction tend to have misguided fears and make uninformed decisions such as voluntary childlessness (VC) or poor medication adherence.

Aims

We aim to understand the correlation between improved knowledge about IBD and Medication Adherence Report Scale (MARS) and Beliefs about Medication Questionnaire (BMQ)

Methods

Adult women with IBD attending the pregnancy IBD clinic at the University of Alberta from 2014–2018 were enrolled. Each patient completed the Crohn’s and Colitis Pregnancy Knowledge (CCPKnow) questionnaire at baseline and after individualized education delivered at each clinic visit. BMQ and MARS Questionaries were completed using a 0–5 Likert scale at each visit. BMQ and MARS data were analysed using Wilcoxon signed ranks test by comparing pre-conception, intrapartum data (trimester) and post-partum scores. BMQ questions were classified under the BMQ Concerns category and BMQ necessity category for regression analysis.

Results

A total of 117 patients were enrolled in this study. 55 patients with CD (47.1%) and 62 patients with UC (52.9%). Statistically, a significant change was noted when comparing the median Trimester BMQ scores to pre-conception BMQ scores. (Z of -2.667, p=0.008) and Median post-partum BMQ scores to Median pre-conception BMQ scores. (Z of -2.547, p=.011). Trimester BMQ Concerns data had a strong negative correlation with CPPKnow scores (Correlation Co-efficient -.528, p<0.05). Median Trimester MARS data had a strong positive correlation with CPPKnow scores (Correlation Co-efficient 0.644, p<0.05).

Conclusions

Increased CPPKnow scores in patients were correlated with patients that were less concerned about IBD medication use and were noted to have higher medication adherence as reflected in the MARS scores post-intervention. A dedicated pregnancy clinic aimed at improving IBD and pregnancy knowledge in women would encourage greater adherence to IBD medication.

Funding Agencies

None
A77 IMPLEMENTATION OF GUT LINK-IBS; RESULTS OF A SEMI-STRUCTURED INTERVIEW OF PRIMARY CARE PROVIDERS
Authors: Sharma S , Heisler C , Jones J , Stewart M J
Published: February 2022

Background

The Division of Digestive Care and Endoscopy in Halifax, Nova Scotia has had longstanding challenges with GI referral volume outstripping divisional capacity resulting in limited access to specialist care. Many referrals for functional bowel disorders (FBD) are returned to referring providers. Although this helps rationalize limited system resources, it often impairs access to appropriate and necessary GI care. The co-development and implementation of clinical care pathways across gastroenterology and primary care may help to improve access to high-quality GI care.

Aims

The project aimed to engage primary healthcare providers (PHCPs) to identify environmental and behavioral barriers and facilitators for managing undifferentiated lower GI disorders in primary care. Data generated from stakeholder engagement will be used to develop, implement, and evaluate strategies for referral and management of FBD. A real-world, functional clinical care pathway that supports the implementation of evidence-based practices in the diagnosis and management of functional GI conditions within primary care will enhance care and timely access to specialist.

Methods

This is a qualitative study using semi-structured interviews of PHCPs working in Nova Scotia. Interview questions were developed and guided by the evidence-based implementation science frameworks. Physicians were recruited through existing primary care networks. Participants were offered a Zoom™virtual semi-structured interview. A brief intake questionnaire was administered to collect baseline demographics. Interviews were recorded and transcribed for data analysis. Data were categorized into coding schemes and themes were created using an inductive coding approach.

Results

As of October 2021, 9 interviews have been conducted. Average participant age was 44 years, with the majority identifying practice in a group or collaborative care setting (n=7, 78%). Five worked in urban practice settings and the remainder in rural areas. Preliminary major themes included:

1. A lack of satisfaction with access to gastrointestinal care, with most physicians noting it to be worse than access to other specialist services.

2. Management of FBDs were felt to be within the scope of primary care practice

3. Access to diagnostic tests like fecal calprotectin with appropriate education on its use as a diagnostic tool would be useful.

4. PHCP’s suggested care pathways be easy to use, require minimal time, and ideally be implemented within their pre-existing EMR or in paper form.

Conclusions

PHCPs acknowledge a significant burden of undifferentiated lower GI complaints in their practice and poor access to gastroenterology services. All participants were open to helping develop and use a clinical care pathway for the investigation and management of undifferentiated lower GI symptoms. Data collection and analysis are ongoing.

Funding Agencies

None
A79 AIMING TO PROVIDE EARLIER CARE WHILE REDUCING SPECIALTY CLINIC WAIT TIMES: DEVELOPING A RELIABLE PROCESS OF ASSESSING THE ELIGIBILITY OF GASTROENTEROLOGY REFERRALS FOR PRIMARY CARE PATHWAYS
Authors: Budhram D , Neary E , Kelley M , Hookey L
Published: February 2022

Background

Gastrointestinal (GI) diseases are common and are a source of substantial morbidity, mortality, and cost, accounting for the largest share of medical referrals from primary care physicians (PCPs) in Canada. Long wait times and increasing numbers of referrals for GI consultation have thus become a significant issue, and while awaiting consultation many patients experience impaired quality of life. Primary care clinical pathways are structured care plans outlining detailed steps for treating patients with specific GI conditions, supporting the translation of clinical guidelines into local protocols and clinical practice.

Aims

To identify the proportion of referrals sent from PCPs to the Queen’s Gastroenterology division that meet the eligibility criteria for a clinical care pathway.

Methods

A review was conducted to identify the proportion of non-urgent referrals in triage sent from PCPs to the Queen’s Gastroenterology division that met the criteria for a clinical care pathway from July 2019 to May 2020. The reason for referral from PCP to gastroenterology was recorded. Individual patient characteristics included in each referral letter were assessed, including age, sex, GI symptoms or signs, relevant clinical features (i.e. time course of symptoms, frequency of bowel movements), relevant laboratory parameters (i.e. CBC, LFTs, electrolytes) or any investigations ordered to evaluate the cause of the patient’s symptoms or signs by the PCP. Four reviewers assessed an initial sample of 200 referral letters and classified each patient’s eligibility for a primary care pathway (GERD, diarrhea, IBS, dyspepsia, or ineligible). After every 100 referrals, discrepancies were reviewed, and a consensus was reached for each case. Data from 100 subsequent referral letters were collected by two independent reviewers, and the inter-rater reliability was calculated. Following a high level of agreement, the final 70 referrals were assessed by two reviewers.

Results

Out of 370 referrals sent from PCPs to the Queen’s Gastroenterology division from July 2019 to December 2019, a total of 170 (46%) met the eligibility criteria for a clinical care pathway. From the eligible referrals, the proportion of patients in each pathway were as follows: 35% GERD, 12% diarrhea, 34% IBS and 19% dyspepsia. The inter-rater reliability for the first 100 referrals assessed by two independent reviewers was 94% (κ = 0.873).

Conclusions

These findings demonstrate that a significant proportion of the patient population referred from PCPs to Queen’s Gastroenterology would be eligible for a primary care pathway. Future steps include implementing these pathways to determine their effectiveness in reducing wait times and empowering PCPs to care for patients who do not require specialist referral.

Funding Agencies

None
A85 LIKELIHOOD OF ENDOSCOPY CANCELLATION BASED ON VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) COLONIZATION STATUS AND INFECTION CONTROL PRACTICES
Authors: Lee J G , Ou G
Published: February 2022

Background

“Terminal cleaning” is a practice of rigorous cleaning of endoscopy suite following endoscopies for patients colonized with vancomycin-resistant enterocci (VRE) with the intention of reducing VRE transmission. Such practice entails double-wiping all surfaces including the floor with disinfectants before a non-VRE patient can use the endoscopy room. While intuitive, such time-consuming practice is not supported by evidence and may have unintended negative impact on patient access to timely endoscopic evaluation.

Aims

To determine whether terminal cleaning of endoscopy suite for VRE-colonized patients has any negative impact on inpatient access to timely endoscopic evaluation.

Methods

As part of a quality improvement study, inpatient endoscopy data was gathered over a 3-month period between February 2021 and April 2021 at a tertiary centre. EUS, ERCP, and travel cases outside of the endoscopy suite were excluded. The cancellation rates were compared between VRE-colonized patients and non-VRE patients using the Fisher’s exact test. P value of <0.05 was considered statistically significant.

Results

A total of 262 inpatient endoscopic procedures were scheduled and included in the study. Sixty-six (25.2%) of inpatient procedures were cancelled during this period (Table 1). A total of 24 procedures were scheduled for VRE patients, 9 of which were cancelled because of insufficient operating time and two due to concurrent carbapenamase-producing organism carriage and poor bowel preparation. In the non-VRE group, 55 (23.3%) procedures were cancelled for various reasons (Table 1). In subgroup analysis where cancellations related to COVID-19 (n=14) were omitted, VRE patients had a significantly higher rate of procedure cancellations compared to non-VRE patients (42.3% vs. 18.5%; p<0.01).

Conclusions

The overall endoscopy cancellation rate for VRE-colonized patients was higher than those who were non-VRE-colonized. We propose that this is likely secondary to the delays from unnecessary terminal cleans imposed for VRE-colonized patients and await for post-intervention data.

Funding Agencies

None
A90 WHEN DO TRAINEES ACHIEVE COMPETENCY IN PERFORMING ENDOSCOPIC SUBMUCOSAL DISSECTION: A SYSTEMATIC REVIEW
Authors: Kaviani R , Tomaszewski M , Shahidi N C
Published: February 2022

Background

Endoscopic submucosal dissection (ESD) is an established organ sparing curative endoscopic resection technique for the management of pre-malignant and superficially invasive malignant lesions of the gastrointestinal tract. However, little is understood of its learning curve with suggested competency measures including en bloc resection, R0 resection, adverse events and resection speed.

Aims

We aimed to perform a systematic review on when competency is achieved in ESD.

Methods

Two authors independently searched MEDLINE and EMBASE (1946 to Aug 2021) for full-text original citations including grey literature assessing the ESD learning curve. A learning curve was defined as an assessment of competency as a function of increasing trainee experience. Thresholds for competency were defined as en bloc resection ≥ 80%, R0 resection ≥ 80%, perforation rate ≤ 5% and resection speed ≤ 6.67min/cm2.

Results

Forty-three studies (1 esophageal, 11 gastric, 27 colorectum, 4 multiple sites) with 157 trainees and 8780 ESD procedures were included. Baseline experience in esophagogastroduodenoscopy, colonoscopy, endoscopic mucosal resection and ESD were 800–10,000, 100–10,000, 4–700 and 0–300 procedures, respectively. 16 studies used animal model training prior to assessing the ESD learning curve.

En bloc resection, R0 resection, perforation rate and resection speed were used as markers of competency in 33, 29, 28 and 21 studies, respectively. When pooling evaluations where competency was achieved, it was reached in the esophagus, stomach, colorectum and for multiple sites between <10, <10–150, <10–301, and <20–300 procedures, respectively (Table 1). However, competency in R0 resection, perforation rate, and resection speed was not uniformly achieved within 12 studies.

Conclusions

Competency in ESD can be achieved in <10 - 399 procedures, with variability dependent on organ site and baseline level of training. With the widespread adoption of ESD, standardization of training and the assessment of competency are needed.

Funding Agencies

None
A96 RAPID IMPLEMENTATION OF AN EVIDENCE-BASED, VIRTUAL COVID-19 VACCINE EDUCATION CLINIC AT NOVA SCOTIA COLLABORATIVE INFLAMMATORY DISEASE CLINIC (NSCIBD)
Authors: Komeylian H , Jones J , Stewart M , Heisler C , Phalen-Kelly K , Currie B
Published: February 2022

Background

Rapid adaptation of clinical management as well as policy decisions in relation to implementation of COVID-19 vaccination programs for persons living with IBD has been required throughout the pandemic.

Aims

To meet the need for public health-mandated COVID-19 vaccine education for patients living with IBD in Nova Scotia a novel, evidence-based, virtual COVID-19 vaccine educational intervention was developed, implemented, and evaluated.

Methods

An observational, cross sectional, implementation-effectiveness study was conducted at the NSCIBD program between April and July, 2021. The educational intervention consisted of a standardized evidence-based letter describing risks and benefits of COVID-19 vaccine emailed to patients in advance of a virtual clinic appointment. Virtual appointments were offered to all patients contacting the NSCIBD program with questions or concerns about vaccination. During these virtual visits standardized, evidence-based information was provided by a gastroenterologist (n=2) or IBD nurse practitioners (n=2) and patients were provided with an opportunity to address specific disease and treatment related concerns. Following the session, a link to an anonymous questionnaire was distributed via email to evaluate key implementation metrics including satisfaction, appropriateness, usefulness, perceived impact on knowledge and vaccine hesitancy, and recommendations for improvement. Data analysis was descriptive. Group means were expressed as proportions for categorical variables and means for numerical variables.

Results

A total of 298 patients participated in a virtual patient education session of which 265 provided a valid email address and invited to participate in the on-line survey. The response rate was 49% (131/265). Before the session, 48.9% (64/131) expressed vaccine hesitancy. Twenty-six percent (35/131) expressed concerns relating to risks versus benefits of COVID-19 vaccines. Ninety-one percent (119/131) of respondents found the education program helpful. The proportion of those willing to get vaccinated rose from 61% (pre) to 86.3% (post). Only 1.5% (2/131) indicated they would not get vaccinated. Seventy-seven percent (101/131) found the written and virtually administered educational content to be satisfactory. Eighty-eight percent (115/131) of respondents were willing to participate in similar types of virtual education offerings in the future.

Conclusions

Implementation of an evidence-based, multidisciplinary, virtual COVID-19 vaccination education intervention was perceived to be feasible, acceptable, and effective by IBD patients. Further research on innovative, evidence-based, multidisciplinary educational interventions and the impact of these interventions on IBD clinical outcomes are needed.

Funding Agencies

None
A113 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN PATIENTS WITH SURGICALLY ALTERED ANATOMY IN A CANADIAN TERTIARY REFERRAL CENTRE
Authors: Motomura D , Gan S , Byrne M , Donnellan F
Published: February 2022

Background

Endoscopic retrograde cholangiopancreatography (ERCP) has become a mainstay of diagnosis and treatment of pancreatobiliary conditions. Surgically altered anatomy presents unique challenges in the procedure, necessitating creative solutions such as different types of endoscopes and tools. Distinct from regular anatomy, forward viewing scopes are often required for successful cannulation and therapy of the pancreaticobiliary system. To our knowledge, there is limited data on the practice of ERCP in altered anatomy in Canada.

Aims

Our aim is to present outcomes from a large series of patients with surgically altered anatomy who underwent ERCP at a large Canadian referral centre.

Methods

All ERCP procedures at a tertiary referral centre in Vancouver, Canada from Oct 2020 to Oct 2021 were reviewed retrospectively. Inclusion criteria required surgically altered anatomy and attempted ERCP. Liver transplant patients with duct-to-duct anastomosis were not included in the series. Patients with incomplete procedure documentation were excluded. Demographic, procedural and outcome data were collected. Results are presented descriptively and as median + IQR for quantitative data. Procedural success was defined as cannulation and performance of a cholangiogram and/or pancreatogram

Results

A total of 34 procedures met the inclusion criteria during the study period. Twenty-four procedures were on male patients (71%). Nineteen patients (56%) had had previous ERCP. Sixteen patients (47%) had choledocholithasis as the indication for the procedure, 9 patients (26%) had cholangitis and 5 patients (15%) had concerns of neoplasia. Some patients had multiple indications. Seventeen patients (50%) had roux-en-Y anatomy, 8 patients (24%) were post Whipple’s and 6 patients (18%) had Billroth II type anatomy. Other altered anatomy included duodenal switch, and post gastrojejunostomy bypass. The most commonly used endoscope was the adult or pediatric colonoscope (74% of cases). Single balloon enteroscope was used in 5 cases (15%). Overall success rate was 74%. The breakdown of success rate by anatomy is shown in Table 1. One (3%) complication was noted in the form of mild cholangitis, requiring only outpatient antibiotics.

Conclusions

Experience in ERCP in patients with altered anatomy is becoming more pertinent in tertiary care. Cannulation and therapy is more difficult in this cohort, but still successful in the majority of cases. Adverse events remain uncommon. Knowledge of forward viewing ERCP techniques is critical in surgically altered anatomy. Future studies will aim to expand the retrospective cohort for more quantitative analysis.

Funding Agencies

None
A117 MANAGEMENT OF VARICEAL BLEEDING WITH ENDOSCOPIC INJECTION OF N-BUTYL-2-CYANOACRYLATE IN PREGNANCY
Authors: Vukovic S , Gallinger Z
Published: February 2022

Background

Although variceal bleeding is rare in pregnancy, pregnant woman with non-cirrhotic portal hypertension are at greater risk of variceal hemorrhage due to increased splanchnic blood flow. Variceal hemorrhage is associated with increased risk of maternal and fetal mortality. Most documented cases of variceal bleeding in pregnancy report the use of elastic ligation for hemostatic management. Histoacryl glue has become increasingly utilized in the acute management and secondary prophylaxis of gastric and ectopic varices in the general population.

Aims

Evidence surrounding the use of Histoacryl glue in pregnancy is limited. We report two cases of variceal bleeding during pregnancy managed successfully with glue.

Methods

Varices were confirmed endoscopically. Images were obtained and reviewed. Aliquots of injected glue were recorded. Maternal and fetal outcomes were monitored during pregnancy and post-partum.

Results

Case 1: A 39-year-old G4P3L0, presented at 20 weeks gestation following several episodes of hematemesis. Urgent esophagogastroduodenoscopy (EGD) revealed hyperemia and portal hypertensive gastropathy in the fundus. A gastric varix with high-risk stigmata was injected with a total of 9mL of 50/50 Histoacryl/Lipodol and bleeding stopped. The patient returned to the hospital two weeks following discharge with melena. Repeat EGD showed mild portal hypertensive gastropathy with a clot at the site of the previous bleeding. No further intervention was required, and the patient delivered at 37 weeks via elective caesarian-section.

Case 2: A 41-year-old G2P0L1 presented at 26 weeks gestation with severe anemia refractory to five units of blood transfusion. Urgent EGD showed a large gastric varix with recent stigmata of hemorrhage, but no active bleed. A total of 13 mL of 75/50 Histoacryl/Lipidol was injected into the varix with no further bleeding. She delivered by elective caesarian-section at 37 weeks gestation. Repeat EGD performed following delivery showed a larger varix with fresh clot at the inferior portion of the fundus. Due to concern for re-bleeding, a total of 4 mL of 50/50 Histoacryl/Lipidol was injected at the site. CT scan post-partum showed prominent gastric varices with glue visualized within the peripheral branches of the portal vein (Figure 1).

Conclusions

Our cases highlight the successful management of gastric varices using Histoacryl glue in pregnancy. Risks associated with Histoacryl glue include glue embolization, local venous thrombosis, as well as extrusion of glue and ulceration. The general complication rate is quoted between 0.5%-5%. One of the two cases was associated with a maternal complication, with evidence of new portal vein thrombosis following injection. The safety of sclerotherapy in pregnancy with cyanoacrylate remains unclear, and further evaluation of the management of gastric varices in this unique population are required.

Funding Agencies

None